Standout Papers

Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlle... 2024 202659
  1. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials (2024)
    Alexa B. Kimball, Gregor B. E. Jemec et al. The Lancet

Immediate Impact

3 by Nobel laureates 4 from Science/Nature 67 standout
Sub-graph 1 of 24

Citing Papers

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
2025 Standout
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
2025 Standout
1 intermediate paper

Works of Amit Garg being referenced

Bariatric surgery in old age: a comparative study of laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy in an Asia centre of excellence
2015

Author Peers

Author Last Decade Papers Cites
Amit Garg 360 414 161 319 37 1.0k
Zhenling Yao 179 327 97 464 27 1.1k
Hyunee Yim 155 177 223 257 64 1.1k
Samuel Litwin 537 286 113 489 31 1.4k
Dmitri V. Gnatenko 165 189 177 528 36 1.3k
R. W. Baldwin 306 183 120 208 33 946
K A Wright 394 151 80 251 25 852
M.A. Paul 434 161 279 222 40 1.2k
Paul Thompson 306 254 258 369 44 1.1k
Alberts Ds 484 80 138 513 53 1.3k
Salmon Se 422 108 62 474 34 1.0k

All Works

Loading papers...

Rankless by CCL
2026